Chimerix, Inc. develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprises dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trials; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis, which is a medical countermeasure for smallpox. The company was incorporated in 2000 and is based in Durham, North Carolina. As of April 21, 2025, Chimerix, Inc. operates as a subsidiary of Jazz Pharmaceuticals plc.
Metrics to compare | CMRX | Peers Peers - average of corresponding metrics from companies closely matching CMRX: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMRXPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |